Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANALYSIS OF HYPERCHOLESTEROLEMIA PREVALENCE IN THE OUTPATIENT PRACTICE (ACCORDING TO THE ARGO STUDY): PART I

https://doi.org/10.20996/1819-6446-2015-11-3-253-260

Full Text:

Abstract

Aim. To study the level of total cholesterol in patients at high and very high cardiovascular risk in real clinical practice and the correspondence of their follow-up to current guidelines for the treatment of dyslipidemia issued by European Society of Cardiology and European Atherosclerosis Society (2011), as well as Russian Society of Cardiology and Russian National Society of Atherosclerosis (2012).

Material and methods. Patients aged 30 years and older who visited a general practitioner or a cardiologist in an outpatient clinic in the period from October 2013 to July 2014 were included into the study. Every patient filled out a special questionnaire. The total cholesterol measurement was performed without special preparation of the patient with portable photometric blood analyzer, which allows the evaluation of total cholesterol in 3 minutes.

Results. 18.273 patients (58.9% women) were included in the final analysis. Hypercholesterolemia was found in 81.3% women and 78.9% males. In all federal districts the total cholesterol level was significantly above the target and varied from 5.82 to 6.10 mmol/L. At that, statins had not been prescribed to almost half of the patients. Total cholesterol> 5 mmol/L was found in 84.7% of the patients treated with simvastatin, in 75.2% of the patients treated with atorvastatin, in 59% of the patients treated with rosuvastatin. Target level of total cholesterol (<4 mmol/L) was achieved in 2.04-7.38% of the patients at a very high cardiovascular risk.

Conclusion. The situation with the diagnosis and treatment of dyslipidemias in a real clinical practice is far from perfect, despite the availability of information for doctors and patients. The causes of this problem require further investigation.

About the Authors

N. M. Akhmedzhanov
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


D. V. Nebieridze
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. S. Safaryan
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


V. A. Vygodin
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. Yu. Shuraev
EGIS Pharmaceuticals PLC Representation in Russia
Russian Federation
Ivana Franko ul. 8, Moscow, 121108 Russia


O. N. Tkacheva
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia


A. S. Lishuta
I.M. Sechenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia


References

1. Diagnostics and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations. 5 review. Available at: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf. Accessed by 18/06/2015. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские Рекомендации. 5 пересмотр. Доступно на: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf. Проверено 18.06.2015)

2. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769-818

3. Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V. et al. Prevalence of risk factors for noncommunicable diseases in the Russian population in 2012-2013. The study ESSE-RF. Kardiovaskulyarnaya Terapiya i Profilaktika 2014; 6: 4-11. Russian (Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная Терапия и Профилактика 2014; 6: 4-11)

4. Ershova AI, Meshkov AN, Yakushin SS, et al. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the register REKVAZA). Ration Pharmacother Cardiol 2014; 10 (6): 612-6. Russian (Ершова А.И., Мешков А.Н., Якушин С.С. и др. Диагностика и лечение больных с выраженной гиперхолестеринемией в реальной амбулаторно- поликлинической практике (по данным регистра РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии 2014;10(6):612-6)

5. Accutrend Plus user manual. Roche Diagnostics; 2014.

6. Goff DC Jr, Bertoni AG, Kramer H et al. Dyslipidemia prevalence, treatment, and control in the MultiEthnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006;113(5):647-56

7. Sun GZ, Li Z, Guo L, Zhou Y, et al. High prevalence of dyslipidemia and associated risk factors among rural Chinese adults. Lipids Health Dis 2014;13:189

8. Vegazo O, Banegas JR, Civeira F, et al. Prevalence of dyslipidemia in outpatients of the Spanish health service: the HISPALIPID Study. Med Clin (Barc) 2006;127(9):331-4

9. Plana N, Ibarretxe D, Cabré A et al. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Clin Investig Arterioscler 2014;26(6):274-84

10. Zubareva MY, Rozhkova TA, Gornyakova NB, et al. Residual (residual) risk in patients with very high risk with atherogenic dyslipidemia, are on statin therapy. prospective study "crystal". Part 1: The purpose, objectives, design, and baseline characteristics of patients included. Ateroskleroz i Dislipidemii 2013; 1: 26-34. Russian (Зубарева М.Ю., Рожкова Т. А., Горнякова Н. Б., и др. Резидуальный (остаточный) риск у больных очень высокого риска с атерогенными дислипидемиями, находящихся на терапии статинами. проспективное исследование «Кристалл». Часть 1: цель, задачи, дизайн и исходные характеристики включенных пациентов. Атеросклероз и Дислипидемии 2013; 1: 26-34)

11. Shalnova SA, Deev AD. Characteristics of high-risk patients. The results of the epidemiological research and educational programs OSCAR. Kardiovaskulyarnaya Terapiya i Profilaktika 2006; 2: 58-63. Russian (Шальнова С.А., Деев А.Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части научно-образовательной программы ОСКАР. Кардиоваскулярная Терапия и Профилактика 2006; 2: 58-63)

12. Viigimaa M, Erglis A, Latkovskis G, et al. Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS). Medicina (Kaunas) 2014;50(1):44-53

13. Drexel H, Chazelle F, Fauer C et al. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). Wien Klin Wochenschr 2011;123(19-20):611-7

14. Azar ST, Hantash HA, Jambart S et al. Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study. Vasc Health Risk Manag 2014;10:225-35

15. Goodman SG, Langer A, Bastien NR, et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol 2010;26(9):e330-5

16. Zhao S, Wang Y, Mu Y et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis 2014;235(2):463-9

17. Wang F, Ye P, Hu D et al. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China). Atherosclerosis 2014;237(1):99-105

18. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 2012 ;1(6):e001800

19. Liberopoulos E, Vlasserou F, Mitrogianni Z et al. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology 2012;63(3):184-93

20. Sudano I, Hess L, Noll G, Arnet D. Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients. Swiss Med Wkly 2013;141:w13200


For citation:


Akhmedzhanov N.M., Nebieridze D.V., Safaryan A.S., Vygodin V.A., Shuraev A.Y., Tkacheva O.N., Lishuta A.S. ANALYSIS OF HYPERCHOLESTEROLEMIA PREVALENCE IN THE OUTPATIENT PRACTICE (ACCORDING TO THE ARGO STUDY): PART I. Rational Pharmacotherapy in Cardiology. 2015;11(3):253-260. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-3-253-260

Views: 565


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)